Literature DB >> 9326193

Leukaemia presenting as marrow hypoplasia: molecular detection of the leukaemic clone at the time of initial presentation.

A A Morley1, M J Brisco, M Rice, L Snell, L M Peng, E Hughes, S H Neoh, P J Sykes.   

Abstract

Occasional cases of transient marrow hypoplasia in childhood evolve into acute leukaemia. We studied two children who presented with marrow hypoplasia following infection and who developed acute lymphoblastic leukaemia 2-3 months later. A simple polymerase-chain-reaction (PCR) test for monoclonality showed that immunoglobulin heavy-chain gene rearrangements of the same size were present at the times of both hypoplasia and leukaemia, and DNA sequencing confirmed identity of these rearrangements. PCR-based quantification, using patient-specific primers, showed in both patients that the leukaemic clone made up 20-25% of the marrow cells during hypoplasia. In contrast, four patients with typical aplastic anaemia showed only polyclonal B-cell populations in the marrow. We conclude that the leukaemic clone was already present at the time of hypoplasia in the two index patients and that in future a simple PCR test for monoclonality could be used to screen patients with marrow aplasia or hypoplasia for the presence of a monoclonal B-cell population. Patients with monoclonal populations could then be monitored carefully for subsequent development of leukaemia.

Entities:  

Mesh:

Year:  1997        PMID: 9326193     DOI: 10.1046/j.1365-2141.1997.3053122.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Spontaneous remission of acute lymphoblastic leukemia: A case report.

Authors:  Timm Höres; Knut Wendelin; Kerstin Schaefer-Eckart
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

2.  Transient bone marrow hypoplasia preceding T-Cell acute lymphoblastic leukemia: a case report.

Authors:  Ernest Naturinda; Paul George; Joseph Ssenyondwa; Deogratias Bakulumpagi; Joseph Lubega; Peter Wasswa
Journal:  Afr Health Sci       Date:  2021-06       Impact factor: 0.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.